骨髓增生异常综合征(MDS)与继发性急性髓系白血病(sAML)系列分子注释的预后意义
本研究纳入157例至少接受两次二代测序(NGS)评估的MDS、sAML或CMML患者,93%患者在两次NGS之间接受治疗。系列评估中达到突变清除(NGS-)的患者总生存(OS)显著优于突变持续者(中位OS未达到 vs 18.5个月,P=0.002),多因素分析证实(HR 0.14,95%CI 0.03-0.56,P=0.0064)。系列TP53 VAF评估可预测结局,TP53清除为OS更优的独立协变量(HR 0.22,95%CI 0.05-0.99,P=0.048)。
要点
- MDS/sAML患者治疗期间系列NGS评估中达到突变清除(NGS-)与OS显著改善相关。
- VAF自基线变化幅度与治疗反应质量显著相关。
- 系列TP53 VAF评估可预测结局,TP53清除为OS更优的独立协变量。
核心结论
- 本研究强调治疗期间系列NGS的临床价值,并需前瞻性验证NGS阴性作为治疗结局生物标志物。
研究设计与样本
- 研究纳入至少接受两次NGS评估的MDS或sAML患者,共157例(MDS 95例,sAML 52例,CMML 10例),93%患者在两次NGS评估之间接受治疗。
- 采用单因素和多因素Cox回归模型评估NGS轨迹对总生存(OS)的预后影响。
主要发现
- VAF自基线变化幅度与治疗反应质量显著相关。
- 达到NGS-的患者OS显著优于突变持续患者(中位OS未达到 vs 18.5个月,P=0.002),多因素分析证实(HR 0.14,95%CI 0.03-0.56,P=0.0064)。
- 系列TP53 VAF评估可预测结局,TP53清除为OS更优的独立协变量(HR 0.22,95%CI 0.05-0.99,P=0.048)。
局限性
- 原文结论提出需前瞻性验证NGS阴性作为治疗结局生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The implementation of next-generation sequencing (NGS) has influenced diagnostic, prognostic, and therapeutic decisions in myeloid malignancies. However, the clinical relevance of serial molecular annotation in patients with myelodysplastic syndrome (MDS) undergoing active treatment is unknown. MDS or secondary acute myeloid leukemia (sAML) patients who had at least two NGS assessments were identified. Outcomes according to mutation clearance (NGS-) on serial assessment were investigated. Univariate and multivariate Cox regression models were used to evaluate the prognostic impact of NGS trajectory on overall survival (OS). A total of 157 patients (MDS [n = 95]; sAML [n = 52]; CMML [n = 10]) were identified, with 93% of patients receiving treatment between NGS assessments. Magnitude of VAF delta from baseline was significantly associated with quality of response to treatment. Patients achieving NGS- had significantly improved OS compared to patients with mutation persistence (median OS not reached vs. 18.5 months; P = 0.002), which was confirmed in multivariate analysis (HR,0.14; 95%CI = 0.03-0.56; P = 0.0064). Serial TP53 VAF evaluation predicts outcomes with TP53 clearance representing an independent covariate for superior OS (HR,0.22; 95%CI = 0.05-0.99; P = 0.048). Collectively, our study highlights the clinical value of serial NGS during treatment and warrants prospective validation of NGS negativity as a biomarker for treatment outcome.
引用
- Yun S, Geyer SM, Komrokji RS, et al. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. 2020. PMID: 32728186. doi:10.1038/s41375-020-0997-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。